Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 6:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 4,234 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Study Product Clear all
Recruiting Phase 2 Interventional

Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)

NCT04305769
View directory record Official record
Conditions
Clostridioides Difficile Infection, Clostridium Difficile Infection, Clostridium Difficile Diarrhea, Clostridia Difficile Colitis
Interventions
Alanyl-glutamine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 105 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Charlottesville, Virginia • Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 4 Interventional

Genicular and Anterior Femoral Cutaneous Nerve Blocks for Total Knee Arthroplasty

NCT05980546
View directory record Official record
Conditions
Total Knee Replacement, Genicular Nerve Block, Opioid Use
Interventions
Bupivacaine Injection, Dexamethasone injection, Fentanyl, Mepivacaine
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 25, 2026, 6:15 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT02546986
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
CC-486, Pembrolizumab, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
10
States / cities
Glendale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 25, 2026, 6:15 AM EDT
Terminated Phase 1 Interventional

Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells

NCT01783431
View directory record Official record
Conditions
Melanoma
Interventions
Poly ICLC, leukapheresis
Drug · Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle GI Health™: A Study Assessing the Impact of Health and Wellness Products on Gastrointestinal (GI) Health

NCT06999642
View directory record Official record
Conditions
GI Health
Interventions
GI Health Placebo Control, GI Health Active Product
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.

NCT04883593
View directory record Official record
Conditions
Tinea Pedis
Interventions
TA103, Placebo Control
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus

NCT00856284
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Alogliptin, Metformin, Glipizide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,639 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
94
States / cities
Montgomery, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Oct 25, 2026, 6:15 AM EDT
Terminated Phase 4 Interventional Results available

Naltrexone/Bupropion Cardiovascular Outcomes Study

NCT02638129
View directory record Official record
Conditions
Obesity, Cardiovascular Diseases
Interventions
Naltrexone HCl/Bupropion HCl ER, Placebo
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
139
States / cities
Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 3 Interventional Results available

A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

NCT04938427
View directory record Official record
Conditions
Lennox Gastaut Syndrome (LGS)
Interventions
Placebo, Soticlestat
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 55 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
24
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 25, 2026, 6:15 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Intra Uterine Device Insertion in Nulliparous Women

NCT01422226
View directory record Official record
Conditions
Contraception
Interventions
Misoprostol, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 25, 2026, 6:15 AM EDT
Recruiting Phase 2Phase 3 Interventional

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

NCT06788990
View directory record Official record
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo
Drug
Lead sponsor
Bicara Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 3 Interventional Results available

Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis

NCT00432835
View directory record Official record
Conditions
Gastroparesis
Interventions
Gastric Electrical Stimulator, Enterra, Medtronics, Inc.
Device
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 3 Interventional Results available

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03751124
View directory record Official record
Conditions
Uterine Leiomyoma, Uterine Fibroids
Interventions
Relugolix, Estradiol/norethindrone acetate, Placebo for relugolix, Placebo for E2/NETA
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
72
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 2 Interventional Results available

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

NCT05660850
View directory record Official record
Conditions
Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma, Unexplained Chronic Cough, CRC With Chronic Obstructive Pulmonary Disease, CRC With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Interventions
GDC-6599, GDC-6599-matching placebo, Mannitol
Drug · Other · Diagnostic Test
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
8
States / cities
Los Angeles, California • Northridge, California • Coral Gables, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa

NCT00795574
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
infliximab, Placebo Comparator
Drug
Lead sponsor
Florida Academic Dermatology Centers
Other
Eligibility
16 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2008 · Synced Oct 25, 2026, 6:15 AM EDT
Active, not recruiting No phase listed Observational

Impact of GABA Probiotic Lactiplantibacillus Plantarum Lp815 on Sleep Outcomes in Participants with Self-Reported Sleep Disturbance

NCT06789718
View directory record Official record
Conditions
Insomnia (moderate)
Interventions
GABA Probiotic Lactiplantibacillus plantarum Lp815 (5 Billion cfu/dose), Placebo, Optional Sub-Study: Neurotransmitter Urine Test
Dietary Supplement · Other · Diagnostic Test
Lead sponsor
Verb Biotics LLC
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects

NCT04142424
View directory record Official record
Conditions
Metabolic Disorders, Non-alcoholic Steatohepatitis
Interventions
AZD2693, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer

NCT00076024
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Placebo, Docetaxel, AG-013736 (axitinib)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
24
States / cities
Tucson, Arizona • Berkeley, California • Montebello, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2012 · Synced Oct 25, 2026, 6:15 AM EDT
Recruiting Phase 2 Interventional

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

NCT06932263
View directory record Official record
Conditions
Asthma
Interventions
Tozorakimab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
64
States / cities
Bakersfield, California • Huntington Beach, California • La Mesa, California + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 6:15 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Radicle PerformanceTM VKN: A Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes

NCT07802587
View directory record Official record
Conditions
Fatigue
Interventions
Placebo Health Performance Control, Active Health Performance Product
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
35 Years to 60 Years
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 25, 2026, 6:15 AM EDT
Withdrawn Not applicable Interventional

Mepilex Ag vs. Xeroform in Pediatric Patients That Sustain Partial Thickness Burn Injury

NCT04149808
View directory record Official record
Conditions
Second-degree Burn
Interventions
Mepilex Ag (burn dressing), Xeroform Dressing
Device
Lead sponsor
Wayne State University
Other
Eligibility
7 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Comparison of 129Xe MRI With 19F MRI in CF Lung Disease

NCT03482960
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Hyperpolarized Xenon gas, PFP
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Safety and Efficacy of a Single Dose of SKY0402 in Subjects Undergoing Augmentation Mammoplasty

NCT01206608
View directory record Official record
Conditions
Postoperative Pain
Interventions
SKY0402 + bupivacaine HCl, Mid-dose SKY0402 + bupivacaine HCl
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 25, 2026, 6:15 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Alogliptin Pediatric Study

NCT02856113
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Alogliptin Benzoate, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
10 Years to 17 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
34
States / cities
Little Rock, Arkansas • Los Angeles, California • Palmdale, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Oct 25, 2026, 6:15 AM EDT